Professor Kenneth Oye co-authored a commentary that urges regulators to work to prevent abuse following a study that finds that opioids can be home-manufactured by genetically engineering yeast, reports Eryn Brown for The Los Angeles Times. “[A]ll of these technical steps should be done beforehand,” says Oye. “Afterwards, it's too late."
Wall Street Journal reporter Timothy Hay writes about the MIT Hacking Medicine program, a new MIT spin out that aims to examine whether digital technologies have made people healthier. Hay explains that the institute will produce “white papers that offer guidelines on evaluating digital-health programs.”
In an article for The Wall Street Journal, Chris Jacobs writes about a study co-authored by Prof. Amy Finkelstein that examines the utility and efficiency of Medicaid coverage. The study “found that beneficiaries valued Medicaid at 20 cents to 40 cents on the dollar,” writes Jacobs.
MIT researchers have developed a USB-powered stethoscope, reports Vijee Venkatraman for BetaBoston. Venkatraman explains that the stethoscope's companion app, "transforms the device into a low-cost diagnostic tool" that can be used to diagnose lung disease.
Graduate student Tristan Swedish has devised a concept for a device that allows patients to photograph their retinas, according to The Economist. Swedish hopes the device could allow, “people to monitor themselves and, if there are any warning signs, to be advised to see a doctor.”
Miles O’Brien of the PBS NewsHour reports on how scientists are developing cheaper and more efficient tests for Ebola, highlighting Prof. Lee Gehrke’s simple diagnostic kits. Gehrke explains that the test his team developed is “very simple, requires no refrigeration, no power, no special training.”
Emma Cott of The New York Times writes about Huggable, a robotic teddy bear developed by Professor Cynthia Breazeal and researchers at Boston Children’s Hospital for therapeutic use in pediatric hospitals. “It’s not only the health and emotional and recovery benefits, but also logistical and financial, improving efficiency to the overall health system,” says Breazeal.
Philips is moving its North American research headquarters to Kendall Square and has announced a $25 million research alliance with MIT, reports Boston Globe correspondent Karen Weintraub. MIT and Philips have a “resonance on specific technical issues, but also on the approach to innovation,” says Associate Provost Karen Gleason.
MedTech Boston reporter Jenni Whalen writes that Philips has formed an alliance with MIT and plans to move its North American research headquarters to Cambridge. “By moving to Cambridge and collaborating with MIT, its staff and its partners, Philips can work with some of the best minds in the world,” explains Henk van Houten, executive vice president and general manager of Philips Research.
After the release of a paper from U.C. Berkeley researchers detailing how certain strains of yeast may be used to produce opioids, Professor Kenneth Oye coauthored a commentary calling for regulation in the field, writes Lexi Pandell for Wired. “I haven’t seen anything quite like this before,” says Oye.
Rachel Feltman writes for The Washington Post about a commentary by Professor Kenneth Oye that calls for regulation of genetically modified yeast that could potentially produce opiates. “It’s not like tomorrow someone’s going to have a fully integrated, one-pot pathway to go from sugar to morphine,” says Oye. “But it’s coming.”
Michael Le Page writes for The New Scientist about Professor Kenneth Oye’s commentary on research indicating that genetically engineered yeasts could be used to produce opiates. Oye provides a number of policy recommendations to prevent illicit opium production, including outlawing the distribution of opiate-making yeast strains.
Professor Kenneth Oye has coauthored a commentary on a paper that demonstrates researchers may be close to being able to engineer morphine from yeast, writes Nicola Twilley for The New Yorker. The authors worry this “could put illicit opiate production into the hands of many more people, at a much smaller scale.”
Donald McNeil writes for The New York Times about a commentary coauthored by Professor Kenneth Oye on advances that could make it possible to produce morphine using genetically modified yeast. Oye argues for “locking up the bioengineered yeast strains and restricting access to the DNA that would let drug cartels reproduce them.”
The Associated Press writes about Professor Kenneth Oye’s commentary on a paper by researchers at U.C. Berkeley that shows how morphine and other painkillers can be manufactured without opium poppies. Oye calls for regulation in order to prevent abuses.